The U.S. Patent and Trademark Office (USPTO) recently issued a
Notice of Allowance for
The patent, which will not expire at least before 2031, will
cover BL-8020 for the treatment of hepatitis C virus
(HCV)-infected patients who are resistant to anti-HCV
BL-8020 is a proprietary, fixed dose candidate comprising
ribavirin plus hydroxychloroquine (HCQ). BL-8020 is currently in
a phase I/II study, open-label study being conducted across two
sites in France and will enroll up to 32 HCV-infected patients
who have either failed or relapsed after undergoing treatment
with the current standard-of-care. The study is specially
designed to carry on intra-subject analysis so as to ascertain
the extent to which HCQ enhances Ribavirin's antiviral activity.
The company expects partial results from the study in the
beginning of 2014.
The HCV market represents huge commercial opportunity for
BioLineRx. As per data from a 2011 report from Decision
Resources, approximately 180 million people are suffering from
chronic HCV globally. The global HCV market is expected to be
worth $20 billion by 2020 as opposed to $6 billion in 2011.
Currently approved HCV therapies include
Vertex Pharmaceuticals Incorporated
) Incivek and
Merck & Co. Inc.
Apart from BL-8020, other interesting candidates in
BioLineRx's pipeline include BL-1040 for preventing pathological
cardiac remodeling following a myocardial infarction (in CE-Mark
registration trial), BL-5010 for non-surgical removal of skin
lesions (pivotal CE-Mark registration trial to commence), BL-8040
for acute myeloid leukemia (phase II).
BioLineRx carries a Zacks Rank #3 (Hold). Companies that
currently look well-positioned include
Gilead Sciences Inc.
) with a Zacks Rank #1 (Strong Buy).
BIOLINE RX LTD (BLRX): Get Free Report
GILEAD SCIENCES (GILD): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
VERTEX PHARM (VRTX): Free Stock Analysis
To read this article on Zacks.com click here.